What is Wedbush’s Estimate for Chimerix FY2028 Earnings?

Chimerix, Inc. (NASDAQ:CMRX) – Stock analysts at Wedbush lifted their FY2028 earnings estimates for Chimerix in a research report issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of $0.58 per share for the year, up from their prior estimate of $0.47. Wedbush has a “Outperform” rating and a $7.00 price target on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share.

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research note on Tuesday.

Chimerix Stock Performance

Shares of CMRX opened at $5.08 on Wednesday. The company has a market capitalization of $456.90 million, a PE ratio of -5.40 and a beta of 0.35. The company’s 50 day moving average price is $3.68 and its 200 day moving average price is $1.90. Chimerix has a 52 week low of $0.75 and a 52 week high of $5.53.

Insider Buying and Selling at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 20,760 shares of company stock worth $91,175 over the last ninety days. 13.10% of the stock is currently owned by insiders.

Institutional Trading of Chimerix

A number of institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC acquired a new stake in shares of Chimerix in the fourth quarter worth $130,000. Two Sigma Investments LP lifted its stake in shares of Chimerix by 309.1% in the fourth quarter. Two Sigma Investments LP now owns 101,156 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 76,430 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Chimerix in the fourth quarter worth $535,000. Millennium Management LLC lifted its stake in shares of Chimerix by 6.8% in the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock worth $8,900,000 after buying an additional 161,795 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new stake in shares of Chimerix in the fourth quarter worth $13,124,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.